This study did not find an association between the methylation of the ACE2 promoter and the presence of post-COVID-19 fatigue, dyspnea, cognitive or gastrointestinal problems up to one year and a half after the infection in previously hospitalized COVID-19 survivors. Here, ACE2 is linked to COVID-19.